News
Click here for news in Danish.
July 27, 2022 | Press Releases
Bavarian Nordic Receives U.S. and EU Approvals of its Fill and Finish Vaccine Manufacturing Facility July 25, 2022 | Press Releases
Bavarian Nordic Receives European Approval of Extension of Vaccine Label to Include MonkeypoxJune 28, 2022 | Press Releases
Bavarian Nordic Announces Grant of PRIME Eligibility from the European Medicines Agency for its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older AdultsJune 16, 2022 | Press Releases
Bavarian Nordic Provides Update on the Phase 3 Program for its COVID-19 Booster Vaccine CandidateMay 19, 2022 | Press Releases
Bavarian Nordic Secures Vaccine Order from European Country After Confirmed Monkeypox Cases February 28, 2022 | Press Releases
Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead of Phase 3 TrialFebruary 14, 2022 | Press Releases
Bavarian Nordic Announces Breakthrough Therapy Designation for its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older AdultsJune 11, 2021 | Press Releases
Bavarian Nordic Assists Public Health England in Response to New Cases of MonkeypoxJune 07, 2021 | Press Releases
Updated Recommendations from the World Health Organization Further Support Use of Ebola Vaccine Regimen from Johnson & Johnson and Bavarian Nordic May 17, 2021 | Press Releases
Ebola Vaccine Regimen from Johnson & Johnson and Bavarian Nordic Supports World Health Organization in Efforts to Prevent Spread of Ebola in West Africa May 07, 2021 | Press Releases
U.S. Government Exercises Option for Supply of Additional Smallpox Vaccines from Bavarian Nordic January 05, 2021 | Press Releases
Bavarian Nordic to Supply Smallpox Vaccines to Three European CountriesNovember 12, 2020 | Press Releases
Health Canada Extends Approval of IMVAMUNE to Immunization against Monkeypox and Orthopox VirusesAugust 05, 2020 | Press Releases
Bavarian Nordic Announces the Launch of Distribution and Marketing of RabAvert® in the U.S. Supported by a U.S. Commercial Team December 09, 2019 | Press Releases
Vaccine Regimen from Janssen and Bavarian Nordic to Support Republic of Rwanda’s Preparedness Against Ebola OutbreakNovember 14, 2019 | Press Releases
Phase 3 Results of Bavarian Nordic’s Smallpox Vaccine Published in The New England Journal of Medicine November 11, 2019 | Press Releases
Bavarian Nordic Completes Enrollment of Phase 3 Lot-Consistency Trial of Freeze-dried Smallpox VaccineNovember 06, 2019 | Press Releases
Recent Advances in Bavarian Nordic’s Cancer Immunotherapy Platform Published in Nature CommunicationsOctober 31, 2019 | Press Releases
Investigational Ebola Vaccine from Janssen and Bavarian Nordic to Support Outbreak Response in Democratic Republic of the CongoOctober 03, 2019 | Press Releases
Bavarian Nordic Completes Enrollment of Phase 2 Trial in Chordoma PatientsJune 25, 2019 | Press Releases
Bavarian Nordic Applauds Reauthorization of Key U.S. Biodefense ProgramsJanuary 25, 2019 | Press Releases
Bavarian Nordic Completes Enrollment of First Stage in Chordoma Phase 2 TrialJanuary 24, 2019 | Press Releases
Bavarian Nordic Advances Development of Equine Encephalitis Virus VaccineSeptember 19, 2018 | Press Releases
Bavarian Nordic Delivers Smallpox Vaccine to England in Response to Current Monkeypox CasesAugust 21, 2018 | Press Releases
Importance of Smallpox Vaccination Highlighted in Biopreparedness Exercise